These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6754312)

  • 1. Differentiation of genetic versus epigenetic mechanisms of toxicity and its application to risk assessment.
    Stott WT; Watanabe PG
    Drug Metab Rev; 1982; 13(5):853-73. PubMed ID: 6754312
    [No Abstract]   [Full Text] [Related]  

  • 2. Principles of covalent binding of reactive metabolites and examples of activation of bis-electrophiles by conjugation.
    Guengerich FP
    Arch Biochem Biophys; 2005 Jan; 433(2):369-78. PubMed ID: 15581593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of repair processes on dose-response models.
    Downs TD; Frankowski RF
    Drug Metab Rev; 1982; 13(5):839-52. PubMed ID: 6754311
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds.
    Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D
    Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the carcinogenicity and mutagenicity of chemicals. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1974; 546(0):1-19. PubMed ID: 4214379
    [No Abstract]   [Full Text] [Related]  

  • 7. Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms.
    Marin-Kuan M; Cavin C; Delatour T; Schilter B
    Toxicon; 2008 Aug; 52(2):195-202. PubMed ID: 18649906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stochasticity in physiologically based kinetics models: implications for cancer risk assessment.
    Péry AR; Bois FY
    Risk Anal; 2009 Aug; 29(8):1182-91. PubMed ID: 19508449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a molecular equivalent dose: use of the medaka model in comparative risk assessment.
    Hobbie KR; Deangelo AB; King LC; Winn RN; Law JM
    Comp Biochem Physiol C Toxicol Pharmacol; 2009 Mar; 149(2):141-51. PubMed ID: 18722551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose response problems in carcinogenesis.
    Crump KS
    Biometrics; 1979 Mar; 35(1):157-67. PubMed ID: 497333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of in vivo mutation data can inform cancer risk assessment.
    Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiology of bromate-induced cancer and possible modes of action-studies in Japan.
    Umemura T; Kurokawa Y
    Toxicology; 2006 Apr; 221(2-3):154-7. PubMed ID: 16473452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dosimetry as a tool in genetic risk assessment.
    Aaron CS
    Birth Defects Orig Artic Ser; 1988; 24(5):53-78. PubMed ID: 3073818
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologically based models for risk assessment.
    Portier CJ; Hoel DG; Kaplan NL; Kopp A
    IARC Sci Publ; 1990; (104):20-8. PubMed ID: 2228117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the potencies of chemicals that produce genetic damage.
    Peterson AR; Peterson H
    Carcinog Compr Surv; 1985; 10():495-509. PubMed ID: 3904996
    [No Abstract]   [Full Text] [Related]  

  • 17. Criteria for evidence of chemical carcinogenicity. Interdisciplinary Panel on Carcinogenicity.
    Science; 1984 Aug; 225(4663):682-7. PubMed ID: 6463646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical carcinogenesis: a biologic perspective.
    Farber E
    Am J Pathol; 1982 Feb; 106(2):271-96. PubMed ID: 7039332
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of carcinogenesis and biologically based models for estimation and prediction of risk.
    Moolgavkar S; Krewski D; Schwarz M
    IARC Sci Publ; 1999; (131):179-237. PubMed ID: 10505297
    [No Abstract]   [Full Text] [Related]  

  • 20. Statistical measures of risk.
    Hoel DG
    Drug Metab Rev; 1982; 13(5):829-38. PubMed ID: 6754310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.